Guardian Pharmacy Services, Inc. Class A (GRDN)

In the past six months, Guardian Pharmacy Services' stock has been impacted by several key events. The company reported positive Q3 2025 earnings, leading to a stock increase. The stock reached an all-time high. Analyst ratings and price targets were updated. A director purchased company stock. The company reiterated its 2025 guidance and provided a 2026 outlook. Shares experienced a downturn due to sector-wide headwinds. The stock closed higher despite challenging profitability metrics.

The provided information does not explicitly detail demand seasonality for Guardian Pharmacy Services' products and services. Demand is likely to be relatively stable due to the ongoing and essential nature of medication management for residents in long-term care facilities. The company's revenue is primarily generated through reimbursement for dispensed drugs, suggesting a steady revenue stream tied to resident needs rather than seasonal consumer purchasing patterns.

Guardian Pharmacy Services, Inc. (GRDN) provides technology-enabled pharmacy services to residents of long-term healthcare facilities (LTCFs) across the United States, focusing on individualized clinical services, drug dispensing, and administration for lower acuity LTCFs. The company operates within the Consumer Non-Cyclicals sector and the Food & Drug Retailing industry. Its major products and services include individualized clinical, drug dispensing, and administration capabilities, the Guardian Compass platform, GuardianShield Programs, the Order Entry QA Analyzer, and the Medication Spend Analyzer.

Guardian Pharmacy Services operates solely within the United States. The company has expanded its market presence through acquisitions, including those in the Pacific Northwest, and serves over 3,400 facilities nationwide. Its headquarters are located in Atlanta, Georgia.

Guardian Pharmacy Services has generally maintained a positive brand reputation, particularly among analysts, receiving a consensus rating of "Moderate Buy". The company's localized service model is noted for building strong customer loyalty. However, the company experienced a collapse in profitability in fiscal year 2024, faces intense competition, and is subject to concerns over upcoming changes in Medicare Part D drug pricing.

Guardian Pharmacy Services, Inc. has a significant institutional ownership base, with 228 institutional owners and shareholders holding a total of 24,022,919 shares. Major institutional owners include Brown Advisory Inc., BlackRock, Inc., and Wellington Management Group Llp. Key individual insiders who own company stock include Thomas J Jr Salentine, William Bindley and Fred Burke.